Beware of Buzzwords In Psychedelic Healing
By Madison Margolin
Once vilified as "drugs," psychedelics are more often referred to as "medicine" these days. That's all well and good for reducing the stigma, but simultaneously "medicine" comes with its own paradigm—namely that in the traditional use of the word, only people who are "sick" and need "healing" should be taking medicine. In the case of an infection, for instance, one might take "medicine" in the form of antibiotics or, if they choose a non-pharmaceutical route, a concoction of antimicrobial herbs. But when the infection resolves, it would not only be silly, but also potentially detrimental to continue to the regimen, lest one develop a tolerance or immunity to the medicine itself.
But with psychedelics, things get fuzzy: We call them "medicines" to highlight their therapeutic potential and ability to help us "heal" all sorts of psychic wounding, from trauma to anxiety to chronic grief. But what happened to journeying just for fun, or for deepened connection to a loved one, nature, or the Divine? Sure these intentions or effects can also be therapeutic, but should the same term that is "healing" really cover everything from treating war PTSD in a veteran to tripping at a Phish concert? Both contexts may be "psychedelic," as well as restorative, but when the term "healing" covers such a wide range of experience, does it mean anything at all? What's more, when the term "medicine" is used to the extent that it is in the lingo of today's zeitgeist, does it encourage us to stay sick in order to justify all the psychedelic "healing" we need, simply because we want to trip?
To answer these questions and more, we'll explore "healing" as a buzzword and what to do about it. Are there other ways to talk about "healing," and what does "healing" actually mean?
With traditional medications, we tend to avoid needless continued use (unless there's an aspect of addiction or dependence, which is another story). Psychedelics, however, don't slot cleanly into that logic. They can and do relieve profound psychiatric suffering, yet they’re also used to celebrate, to play, to deepen intimacy, to encounter the sacred. Lumping those uses under the single banner of “healing” softens important distinctions and puts the word at risk of becoming hollow — a marketing gloss that flattens clinical evidence, spiritual practice, and simple human joy into one category. In this story, we’ll map the registers of psychedelic use, clarify what healing can reasonably mean in each, and offer alternatives — sharper language, better consent, and ethical practices — so the word “healing” can regain specificity instead of serving as a one-size-fits-all sales pitch.
In the past two decades the language around psychedelics has shifted. Recasting "drugs" to "medicine" and "tripping" to "healing" didn’t happen by accident; it grew out of a deliberate clinical renaissance and a pragmatic strategy to move these substances out of the margins and into research hospitals, funders’ portfolios, and regulatory frameworks.
The clinical renaissance is central. After decades of prohibition, a wave of carefully designed trials began to demonstrate consistent, and sometimes dramatic, therapeutic benefits. Psilocybin showed promise for treatment‑resistant depression and end‑of‑life distress; MDMA produced striking reductions in PTSD symptoms in Phase 2 and early Phase 3 trials. Those results mattered because they translated psychedelic effects into the language regulators understand: symptom reduction, remission rates, tolerability, and measurable follow‑up outcomes. Scientists, clinicians, and hospital programs leaned into medical terminology to describe protocols, dosing regimens, screening procedures, and integration practices. Calling these interventions “medicine” did political work, framing psychedelics as tools for healing rather than vectors of moral panic.
Media, advocacy, and market dynamics amplified that framing. Journalists and documentarians, eager for a compelling narrative, often foregrounded clinical breakthroughs and human interest stories: veterans brought back from crippling flashbacks, terminally ill patients finding peace. Advocacy groups adopted medical language to lobby for rescheduling and access; funders and venture capitalists used it to justify investment. “Medicine” sells: to policymakers it signals control and safety; to insurers and hospitals it promises a return on an evidence-based intervention. The wellness industry, meanwhile, co-opted the rhetoric, packaging retreats, microdosing products, and integration coaching under the same therapeutic umbrella. Marketing copy adopted “healing” as shorthand for transformation, making the term culturally ubiquitous.
That ubiquity tracked a broader cultural shift. Psychedelics migrated from countercultural scenes—where “tripping” was experimental, recreational, or revolutionary—into psychotherapy offices, curated retreats, and weekend wellness practices. The emphasis moved from rebellion to repair, from expressive excess to structured processes. Clinicians emphasized screening, safety, and follow‑through; retreat organizers built syllabi around integration. Even casual users adopted vocabulary borrowed from therapy: “set and setting,” “integration,” “aftercare.”
The consequence is a tradeoff. Medicalizing psychedelics yielded legitimacy, research funding, and life‑saving treatments for many—but it also narrowed the conceptual space. When “medicine” and “healing” become the dominant metaphors, other valid registers—play, ritual, communal celebration, aesthetic exploration—can be obscured or delegitimized. The language that opened doors for regulation and care now risks flattening a diversity of practices into a single frame that emphasizes pathology and remediation over nuance.
Psychedelic experiences don’t sit in a single box. They occur across overlapping registers—clinical, ritual, recreational, and wellness—each with different aims, norms, risk profiles, and ways of judging success. Lumping them together under one headline like “healing” undermines important distinctions. Here’s a practical map of the major registers, what people hope to get from them, and where the lines blur.
Speaking About Psychedelic Healing in a Clinical/therapeutic Register:
This is the register most people mean when they invoke “medicine” in the strict sense. The primary goals are symptom reduction and functional improvement: measurable decreases in PTSD flashbacks, fewer depressive episodes, reduced substance use, better sleep, restored work and social functioning. Settings are controlled: clinics or hospital-affiliated programs with medical screening, preparatory psychotherapy, protocolized dosing, trained therapists or physician oversight, and structured integration sessions. Outcomes are judged with validated metrics—CAPS for PTSD, MADRS for depression, relapse rates for addiction—and by follow-up assessments over months or years.
Examples are increasingly familiar: MDMA‑assisted therapy for PTSD, psilocybin for treatment‑resistant depression or existential distress in terminal illness, and ketamine clinics for acute suicidal ideation. In this register, psychedelics are tools within a therapeutic model; they catalyze processes that therapists help patients integrate into daily life. Safety, informed consent, and evidence hierarchy are paramount; misuse or overclaiming can harm both individuals and the field.
Exploring the Ritual/spiritual Register
Here the aim is not symptom remission so much as meaning-making, sacred encounter, or initiation. Practices draw on ceremonial structures—ayahuasca circles, traditional medicine practices, neo-shamanic retreats—with set roles for elders, facilitators, or shamans and communal ethics that frame experience as relational and sacred. Outcomes are subjective but profound: reports of awe, connectedness, encounters with numinous realities, and long-term shifts in worldview or values.
Metrics, where used, tend to be phenomenological: mystical experience questionnaires (MEQ), spiritual well‑being scales, or narrative accounts. Respect for lineage, ritual integrity, and cultural context matters; when ceremonies are divorced from their source traditions or commodified, ethical and political concerns arise. Unlike clinical settings, ritual spaces may prioritize communal meaning over standardized measures, and success is often judged by coherence of ritual, depth of participation, and perceived transformation.
Beyond Healing: Psychedelics in the Recreational/social Register
This is the register of parties, festivals, concerts, and social microdosing among friends. The goals are play, bonding, creativity, and ecstatic communion. Experiences here are typically less structured and more ephemeral—dancing through the night, creative bursts, laughter, a felt sense of social belonging. Metrics are informal: anecdotes about “the best night,” new friendships, or temporary mood elevation.
Risks in this register are concentrated around environment and lack of support: dosing uncertainty, adulterants, dehydration, psychological destabilization in unsafe settings, or post-event crashes without integration. Harm‑reduction practices (testing substances, buddy systems, chill spaces, on-site medical tents) matter most here. Treating these experiences as “healing” can be misleading; they can be restorative and growth-promoting, but they’re not substitutes for clinical care when pathology is present.
Personal Growth/wellness Register
Between therapy and play sits a large domain devoted to flourishing: microdosing experiments, periodic retreats aimed at creativity or resilience, coaching-based integration, and psychedelic-assisted personal development. Goals are long-term optimization rather than fixing a diagnosed illness—improving creativity, sharpening empathy, cultivating resilience, or deepening spiritual practice as part of everyday life.
Outcomes are often self-reported improvements in productivity, mood, relationships, and life satisfaction. Evidence here is mixed and nascent: some people report meaningful gains, while controlled trials are few and results uneven. This register benefits from disciplined integration, ethical guides, and caution about turning self-improvement into consumerist projects.
Overlaps and Boundary Cases
Real-world use rarely conforms to tidy categories. Couples’ therapy using psychedelics may bring clinical aims into a ritual container; a festival might host harm-reduction clinics that look clinical but operate in recreational contexts. Retreats marketed as “transformative” often blend ceremonial, therapeutic, and wellness elements; participants may seek joy and symptom relief in the same trip.
These boundary cases are where language—and care—matters most. Clear intake, matched setting to intention, and honest communication about goals, risks, and follow-up can prevent harm. Rather than pretending these registers are interchangeable, acknowledging their distinct aims lets practitioners, facilitators, and participants choose contexts that fit intentions and provides a basis for realistic expectations and ethical practice.
“Healing” is a tidy, consoling word, promising repair, wholeness, and an end to suffering. But unpacking it shows that it’s actually a cluster of related but distinct ideas: a process and an outcome, multiple domains of change, different timescales, and varying criteria for success. Those differences matter because they determine what a psychedelic experience can plausibly do, how we measure it, and how people should set expectations
First: process versus outcome. Healing as process names the work that happens during and after a psychedelic experience: the integration that translates insight into new habits, the relational labor of repairing trust, the therapeutic practices that consolidate gains. In this register, psychedelics are catalysts—occasioning emotional breakthroughs, embodied releasings, or fresh perspectives—but not the sole agents doing the work. Healing as outcome, by contrast, is a state: the absence or reduction of symptoms (fewer panic attacks), restored functioning (returning to work), or a felt sense of wholeness. Confusing the two leads to marketing claims that a single session will “cure” chronic conditions when, more often, lasting change depends on sustained integration and structural supports.
Next: domains of healing. Not all healing looks the same. Physical healing—tissue repair or infection resolution—is rarely the primary effect of classic psychedelics. Psychological healing covers trauma processing, reduced anxiety or depression, improved emotion regulation. Social healing includes mended relationships, better social functioning, and restored roles within family or community. Existential and spiritual healing encompass shifts in meaning, reduced death anxiety, mystical experiences, and reoriented values. A single psychedelic session might touch several domains (a veteran might report fewer flashbacks and a renewed sense of purpose), but outcomes should be described in domain-specific terms rather than as a catchall “healing.”
Temporal scales complicate things further. Some effects are acute and dramatic: a cathartic release, a sudden reframing of a memory, immediate relief from suicidal ideation in ketamine treatment. Many changes unfold over intermediate timescales: weeks or months of integration work, behavioral changes, and relational repair. Long-term identity changes—altered values, life trajectories, vocational shifts—can take years and often depend on continued practice, community support, and life circumstances. When advocates use “healing” without temporal qualifiers, they flatten these distinctions, implying permanence from what might be transient relief.
So what counts as “healed”? Different registers use different criteria. Clinicians look for functional improvement and symptom reduction measured on validated scales: decreased CAPS scores, fewer depressive episodes, improved sleep and occupational functioning. Individuals might judge healing by subjective wellbeing — increased life satisfaction, reduced suffering, or an enduring sense of peace. Narrative coherence matters: people often report healing when they can reframe a life story that previously centered shame or helplessness into one with agency and meaning. Relational repair — restored trust, better communication, renewed intimacy — is its own outcome and can be as consequential as symptom remission. These criteria don’t always align: a person may feel subjectively better yet still meet diagnostic thresholds, or show improved metrics while lacking a coherent life narrative.
Why does this semantic slippage matter? Because a single label obscures the specificity that patients, participants, clinicians, and communities need. Calling everything “healing” erases distinctions between momentary solace and sustained recovery, between a mystical peak and a clinically significant remission, between a festival’s communal high and a veteran’s meticulously supervised therapy protocol. That elision breeds confusion: people expect cures where only catalysts are available; markets sell transformation as a commodity; clinicians struggle to set realistic consent and follow-up. It can also moralize suffering—implying a binary between healed and unhealed that stigmatizes ongoing struggle.
If we’re going to keep “healing” in our vocabulary, we should pluralize and qualify it. Name the process or the outcome; specify the domain and the timescale; use concrete criteria when possible. Saying “this protocol reduces PTSD symptoms and improves social functioning over six months” is more useful than claiming it “heals trauma.” Precision honors both the power and limits of these medicines and helps people choose contexts and supports that match the kind of healing they actually seek.
“Healing” is a warm, morally freighted word, and that makes it powerful—but also dangerous when it’s used as an all-purpose gloss for any and every psychedelic experience. Treating “healing” as a catchall buzzword produces predictable harms across individual, clinical, cultural, and commercial domains. Below are the main risks and how they play out.
Being Cautious of Inflated Expectations
When marketing materials, journalists, and influencers promise “healing,” people arrive with unrealistic beliefs about what a session will deliver. That inflation fuels several downstream problems: placebo-driven short-term improvements that fail to persist, precipitous disappointment when outcomes fall short, and higher dropout from proven treatments when people feel “cured” or betrayed. Overselling also distorts research participation: volunteers may enroll chasing guaranteed transformation rather than consenting to uncertain outcomes, contaminating study samples and complicating interpretation of results.
Moralization and Pathologizing
Casting experiences in the idiom of healing can moralize personal struggles. If healing is framed as a binary—either you’re healed or you’re broken—then ongoing difficulties become moral failures rather than aspects of human life. That framing stigmatizes normal forms of suffering, frames resilience as a personal deficit, and pressures people to pursue repeated interventions to demonstrate their progress. Conversely, it can infantilize those who don’t seek “healing,” implying they’re avoiding growth or shirking responsibility.
Market Harms and Commodification
“Healing” is marketable. The retreat and wellness industries have seized the term to sell packaged transformation: luxury ceremonies, guaranteed breakthroughs, and expensive integration packages. That commercialization produces predatory dynamics—vulnerable people paying premium prices for unregulated services, retreat centers overstating benefits, and a cottage industry of paraprofessionals without adequate training. The result is uneven quality, safety lapses, and exploitation masked as benevolent care.
Clinical harms from blurred evidence:
When clinical terminology migrates into popular usage without caveats, evidence hierarchies collapse. Anecdotal accounts and small open-label studies get conflated with randomized controlled trials. Clinicians may feel pressure to promise dramatic outcomes that the evidence doesn’t support. Patients might forgo standard treatments in favor of unproven psychedelic alternatives, or substitute poorly supervised retreat experiences for medically indicated care. The erosion of clear boundaries undermines informed consent: people cannot weigh risks and benefits if claims are inflated or evidence is obscured.
Cultural Appropriation and Spiritual Bypass
Using “healing” as a universal stamp flattens and decontextualizes complex indigenous and syncretic practices. Ceremonial medicines often come embedded in ethical systems, cosmologies, and long-term communal obligations; marketing them as generic “healing” removes that context. That appropriation is not just cultural theft—it's an ethical harm that strips communities of agency and misrepresents the practices’ purposes. Relatedly, “healing” can encourage spiritual bypassing: using transcendent experiences to avoid necessary psychotherapeutic work, social repair, or political action. A mystical peak marketed as healing can become a palliative that lets structural problems remain unaddressed.
Social and Behavioral Risks
Language that equates psychedelic use with healing creates perverse incentives. If repeated sessions are framed as necessary to sustain or demonstrate healing, people may rely on substance-facilitated states rather than developing longer-term coping strategies. This dynamic can foster psychological dependence on the experience, strained finances, or cycles of repeated retreat attendance. On a social level, it can produce hierarchies within communities where the frequency or intensity of psychedelic use is valorized as evidence of spiritual or moral progress.\
Compounded Harms
These risks don’t operate in isolation. Inflated expectations feed the market; commodification magnifies spiritual bypass and cultural harm; blurred evidence corrodes clinical safeguards; and moralizing language deepens stigma for those who don’t conform. Together they can erode public trust, invite regulatory backlash, and harm the very people proponents claim to help.
Mitigating the Harms
The antidote to these risks is disciplined specificity. Use domain‑specific language (symptom reduction, integration, catalytic experience), time-bound claims (short‑term relief vs. durable change), and clear evidence qualifiers. Retreats and service providers should publish scope statements, safety protocols, staff qualifications, and realistic outcome statistics. Clinicians must preserve rigorous consent practices and distinguish early promising data from established treatments. Finally, honoring indigenous contexts, centering community leadership, and concretely addressing structural determinants of suffering will help prevent the flattening and commodification of sacred practices.
“Healing” need not be abandoned, but it must be earned. When the term is used precisely and ethically, it can describe real change; when it’s a marketing blanket, it causes harm.
If “healing” has become a fuzzy, catchall term, the fix starts with language: more precise, more modest, and better matched to the intention, evidence, and context of a given psychedelic encounter. Below are practical alternatives and communication strategies that preserve the power of these experiences while reducing hype, minimizing harm, and clarifying expectations.
Domain-specific Terms
Use words that name the domain of change rather than a generic cure. Clinically minded phrasing includes “symptom reduction,” “remission,” and “functional improvement” (e.g., “reduces PTSD symptoms,” “improves sleep and daily functioning”). For the intrapsychic work that follows a session, say “integration” or “integration support” instead of implying the medicine did all the work. For the moment of insight, use “insight,” “affective breakthrough,” or “cognitive reframing.” For shifts in life orientation, use terms like “recalibration,” “reconnection,” “meaning‑making,” “resilience‑building,” or “creative exploration.” These terms point to what changed and where, helping people set realistic goals and choose appropriate supports.
Process-focused Verbs
Language that highlights psychedelics as occasioning forces avoids deterministic promises. Prefer verbs such as catalyze, facilitate, occasion, open, reveal, or enable. Saying “psilocybin can catalyze new perspectives that therapists and clients then integrate” conveys that the medicine creates opportunity but does not guarantee outcomes. This framing also foregrounds participant agency and the importance of integration work, community, and follow‑up.
Temporal Qualifiers
Add timebound language to distinguish fleeting effects from durable change. Use phrases like “immediate relief,” “short‑term symptom reduction,” “a catalyst for long‑term change,” or “requires ongoing practice and integration.” Acknowledge uncertainty where evidence is preliminary: “some trials show reductions in depressive symptoms at six months” is clearer and more honest than “psilocybin heals depression.” Temporal precision helps participants and funders understand follow-up needs and prevents expectations of instant miracles.
Audience-tailored Language
Different audiences need different vocabulary.
- Clinicians and researchers: emphasize validated outcomes, effect sizes, confidence intervals, contraindications, and how psychedelic‑assisted protocols fit into broader treatment plans. Use terms like “remission rates,” “randomized controlled data,” and “integration protocols.”
- Retreat organizers and facilitators: be explicit about scope (ceremony, community work, somatic practices), qualifications of staff, safety procedures, and realistic outcomes. Use language like “facilitates relational reconnection” or “supports existential exploration” rather than promising cures.
- Community organizers and harm‑reduction groups: prioritize practical, nonjudgmental language—“safer use,” “peer support,” “aftercare networks,” and “community integration spaces”—that meets people where they are.
- Policymakers and funders: frame arguments in terms they respond to: health burden, cost‑effectiveness, equity, and measurable outcomes. Use "reduces symptom burden," "improves functional outcomes," and "expands evidence‑based care" while acknowledging plural cultural practices.
Examples of Reframed Messaging (Before → After)
- Before: “This retreat will heal you.”
After: “This retreat facilitates reconnection and offers structured integration to support personal insight and relational repair.”
- Before: “Psychedelics heal trauma.”
After: “Clinical protocols combining psychedelics and psychotherapy have shown significant reductions in PTSD symptoms for many participants; outcomes depend on screening and integration.”
- Before: “Take this medicine to find yourself.”
After: “This medicine can catalyze periods of deep reflection and new perspectives; integration practices help translate insight into daily change.”
- Before: “Microdosing heals your brain.”
After: “Some users report improved focus or mood with microdosing, but controlled evidence is limited; consider structured monitoring and professional guidance.”
Practical Framing Tips
- Pair any claim with scope and limitation: name the population, context, and evidence level (e.g., “In controlled studies of adults with treatment‑resistant depression, psilocybin plus therapy has produced…“).
- Favor verbs of facilitation over cure. Let participants know they are co‑agents in change.
- Include next steps in messaging: “If you seek symptom relief, consult a clinician; if you seek spiritual experience, plan for community and integration.”
- Normalize plural outcomes: acknowledge that experiences can be therapeutic, recreational, spiritual, or some combination—each valid but different.
Language shapes practice. Being specific doesn’t make psychedelics less powerful; it makes their benefits and limits legible, which protects participants, preserves clinical credibility, and respects the diverse traditions and intentions that surround these medicines. Use words that guide action, clarify expectation, and invite ethical practice.
Clinicians and Researchers
Be rigorous in language and practice. Informed consent should name probable benefits, known risks, evidence strength, and alternatives—avoid shorthand like “will heal.” Set measurable, collaboratively decided goals (e.g., 30% reduction in MADRS score, improved sleep, return to work) and use validated outcome metrics to track progress. Describe the intervention precisely: agent, dose range, number of sessions, therapist roles, medical screening, and integration supports. Resist marketing hyperbole; when discussing early or preliminary data, say so (e.g., “early randomized trials show X at 6 months in selected populations”). Provide clear follow‑up plans and referral pathways for nonresponders or adverse reactions.
Retreat Centers and Hosts
Be explicit about scope: state whether you offer ceremonial hosting, psychotherapy, somatic work, or a mix. Publish staff qualifications and roles, screening criteria, emergency protocols, and integration resources. Implement safety standards—medical and psychiatric screening, informed consent, on‑site emergency plans, sober support people, and post‑retreat follow‑up. Offer affordable integration options (sliding scale group sessions, alumni groups) and be transparent about pricing and what is included. Avoid promising cures; instead describe plausible outcomes (e.g., “may support relational insight and renewed commitment when followed by integration work”).
Community Communicators and Influencers
Use cautious, non‑absolutist language. Don’t claim universal healing; instead share personal accounts as such and flag them as anecdotal. Include limits and contraindications in public posts (e.g., “not appropriate for people with a history of psychosis or uncontrolled bipolar disorder”). Promote harm reduction: dose guidance, testing, set and setting, buddy systems, chill spaces, and local emergency contacts. Link to vetted resources (harm‑reduction groups, integration therapists). Model humility: cite sources when possible and encourage readers to consult qualified professionals when seeking clinical outcomes.
Helpful Advice For Participants
Clarify your primary intention before engaging: “therapy” (symptom relief), “spiritual exploration” (meaning-making), “social/recreational” (connection/joy), or “creative/workshop” (problem solving). Choose a setting that matches intention—clinical protocols for diagnosable conditions, trained ceremonial contexts for spiritual work, community spaces with harm-reduction for recreational use. Plan for integration: schedule time off, identify people to debrief with, consider therapy or peer integration groups, and create actionable next steps (behavioral experiments, journaling, rituals). Watch for signs of overreliance—repeated use to avoid life problems, escalating frequency or spending, or skipping other care—and seek professional help if use feels compulsive.
Language influences regulation, funding, and access. Framing psychedelics primarily as “medicine” helped open clinical pathways, research funding, and insurance interest—but it also shapes who qualifies for care and which practices gain legitimacy. Strictly biomedical frames can privilege diagnostic thresholds and clinical gatekeepers, leaving out community-based, ritual, or preventative uses that people also value.
Equity concerns arise when access requires diagnosis, money, or geographic proximity to clinics. Cultural humility must be central: indigenous and traditional practices deserve ethical engagement, benefit sharing, and respect for sovereignty rather than extraction and commodification. Who defines “legitimate” use matters for both justice and efficacy.
Regulatory traps are real. Over-medicalization can push at‑home, communal, and ceremonial healing into illegality or irrelevance, or conversely drive commodified retreat markets that exploit regulatory loopholes. Licensing models that only recognize clinician‑led care risk excluding trained community practitioners and elders whose knowledge is essential to certain registers of practice.
A sensible policy stance is pluralistic: recognize multiple valid use-cases—clinical, ceremonial, communal, and recreational—and create pathways for each that prioritize safety, training, and ethical standards. Standards could include clinician licensure for medical protocols; certification programs emphasizing cultural competence for facilitators; funded harm‑reduction and integration services in communities; and protections for indigenous stewardship. Invest in comparative effectiveness research across settings, subsidize access for underserved populations, and require transparency in marketing and outcome reporting. This pluralism preserves clinical rigor without erasing cultural practices or community autonomy, and it reduces the incentive to oversell “healing” as a one‑size‑fits‑all solution.
“Healing” will remain a meaningful word—comfortable, hopeful, and evocative—but it should no longer be the default, catchall term for everything psychedelic. Precision protects people: it sets realistic expectations, clarifies consent, guides appropriate setting choice, and curbs exploitation. Use multidimensional language that names domains (symptom reduction, integration, reconnection), verbs that describe facilitation (catalyze, occasion), and temporal qualifiers (immediate relief, catalyst for long‑term change). Clinicians must ground claims in evidence; hosts must publish scope and safety; communicators must avoid universal claims; participants must match intention to setting and plan for integration.
Words shape practice. If writers, clinicians, community leaders, and participants commit to finer language and transparent ethics, we can preserve psychedelics’ genuine potential without letting “healing” become a hollow sales pitch. Choose the term that fits the aim, and let that accuracy be an ethic as much as a style.
Madison Margolin is a journalist and educator who cofounded the psychedelic magazine DoubleBlind. She is the author of Exile and Ecstasy: Growing up with Ram Dass and Coming of Age in the Jewish Psychedelic Underground. Her writing has been featured in outlets like Rolling Stone, VICE, and Playboy.
